Dive into the recent updates, including Jeremy’s share purchase, which further demonstrates his support & belief in Poolbeg Pharma.
Cathal Friel, Chairman said: Both Jeremy and I have been delighted to increase our holdings in Poolbeg in the past number of days, we are both great believers in Poolbeg’s potential and our ability to repeat the success of Amryt Pharma, with a focus upon developing sustainable and profitable revenues over a relatively short period of time.
We have made excellent progress since IPO in building a highly attractive pipeline of high value programmes including POLB 001, which has a market opportunity of over $10 billion. With an industry leading team in place to execute, we are well placed to accelerate the growth of the Company and to generate value for shareholders.
Following the Purchase, Jeremy holds 873,497 ordinary shares representing approximately 0.17 per cent of the Company’s issued share capital.
Poolbeg Pharma plc is a biopharmaceutical company committed to the development and commercialisation of innovative medicines that address critical unmet medical needs with a growing emphasis on rare and orphan diseases. We have built a robust development pipeline of ground breaking products and are focused on strategically commercialising approved and marketed drugs to fund the development of our robust pipeline of ground breaking products.
